Ivor Royston
Director/Board Member chez VIRACTA THERAPEUTICS, INC.
Fortune : 798 337 $ au 31/03/2024
Profil
Ivor Royston is the founder of Hybritech, Inc. (founded in 1978), IDEC Pharmaceuticals Corp.
(founded in 1986), IDEC Corp.
(United States) (founded in 1986), and Forward Ventures Services LLC (founded in 1993).
He is currently the President, Chief Executive Officer & Director at Viracta Subsidiary, Inc. (since 2015), a Director at Viropro, Inc. (since 2016), a Director at CONNECT, and a Director at Viracta Therapeutics, Inc. (since 2022).
He has previously held positions as President, Chief Executive Officer & Director at Sunesis Pharmaceuticals, Inc., President & Chief Executive Officer at Sidney Kimmel Cancer Center, Chairman at Morphotek, Inc., Chairman at TargeGen, Inc., Director at Corautus Genetics, Inc., Director at CancerVax Corp., Director at Favrille, Inc., Independent Director at Biocept, Inc., Director at MyMedicalRecords, Inc., Independent Director at Syndax Pharmaceuticals, Inc., Director at Avalon Pharmaceuticals, Inc., Director at Amgen Rockville, Inc., Director at LigoCyte Pharmaceuticals, Inc., Director-Clinical Immunology at San Diego Cancer Center, Director at HemaQuest Pharmaceuticals, Inc., Director at Altair Therapeutics, Inc., Independent Director at MMRGlobal, Inc., Director-Clinical Immunology at the University of California, and Trustee at La Jolla Playhouse, Inc. He holds undergraduate and doctorate degrees from The Johns Hopkins University (conferred in 1967 and 1970, respectively).
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 25/02/2024 | 782 683 ( 1,99% ) | 798 337 $ | 31/03/2024 | |
BIOCEPT, INC.
0,00% | 28/02/2023 | 2 ( 0,00% ) | 0 $ | 31/01/2024 |
Postes actifs de Ivor Royston
| Sociétés | Poste | Début |
|---|---|---|
| VIROPRO INC. | Director/Board Member | 08/01/2016 |
| VIRACTA THERAPEUTICS, INC. | Director/Board Member | 01/10/2007 |
CONNECT
 CONNECT Miscellaneous Commercial ServicesCommercial Services CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA. | Director/Board Member | - |
Viracta Subsidiary, Inc.
 Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Chief Executive Officer | 01/01/2015 |
Anciens postes connus de Ivor Royston
| Sociétés | Poste | Fin |
|---|---|---|
| BIOCEPT, INC. | Director/Board Member | 13/10/2023 |
| SYNDAX PHARMACEUTICALS, INC. | Director/Board Member | 01/03/2017 |
| MMRGLOBAL, INC. | Director/Board Member | 11/08/2016 |
Altair Therapeutics, Inc.
 Altair Therapeutics, Inc. Medical DistributorsDistribution Services Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry. | Director/Board Member | 09/03/2011 |
| LigoCyte Pharmaceuticals, Inc. | Chief Executive Officer | 01/04/2010 |
Formation de Ivor Royston
| The Johns Hopkins University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| VIROPRO INC. | Health Technology |
| BIOCEPT, INC. | Health Technology |
| SYNDAX PHARMACEUTICALS, INC. | Health Technology |
| VIRACTA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 23 |
|---|---|
Corautus Genetics, Inc.
 Corautus Genetics, Inc. Pharmaceuticals: MajorHealth Technology Corautus Genetics Inc. is a biopharmaceutical company, which manufactures gene therapy products for the treatment of cardiac and vascular disease & peripheral vascular disease. It is located in Atlanta, GA. | Health Technology |
Hybritech, Inc.
 Hybritech, Inc. Miscellaneous Commercial ServicesCommercial Services Hybritech, Inc. provides prostate diagnostic testing services. The company is headquartered in San Diego, CA. | Commercial Services |
| CancerVax Corp. | Commercial Services |
| Favrille, Inc. | Health Technology |
Morphotek, Inc.
 Morphotek, Inc. Miscellaneous Commercial ServicesCommercial Services Morphotek, Inc. operates as a biotechnology company. It develops and distributes biopharmaceutical products. The firm leverages its Morphodoma and Libradoma platform technologies to develop and research a pipeline of preclinical and clinical stage monoclonal antibodies for the treatment of cancer, inflammation and infectious diseases. The company was founded by Nicholas C. Nicolaides, Luigi Grasso and Philip M. Sass in May 2000 and is headquartered in Exton, PA. | Commercial Services |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
TargeGen, Inc.
 TargeGen, Inc. Pharmaceuticals: MajorHealth Technology TargeGen, Inc. manufactures vascular biopharmaceutical products. The company was founded by David A. Cheresh and Peter G. Ulrich in 2001 and is headquartered in San Diego, CA. | Health Technology |
MyMedicalRecords, Inc.
 MyMedicalRecords, Inc. Commercial Printing/FormsCommercial Services MyMedicalRecords, Inc. provides web-based personal health record and vital document storage solutions. It includes documents, images, and voice mail messages to be transmitted in and out of the MMR system using a variety of methods like fax, file upload, and email. The company was founded by Russel Armstrong and Robert H. Lorsch in 2005 and is headquartered in Los Angeles, CA. | Commercial Services |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Health Technology |
Avalon Pharmaceuticals, Inc.
 Avalon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avalon Pharmaceuticals, Inc. was a biopharmaceutical company focused on the discovery, development and commercialization of cancer therapeutics. The company was founded in November 1999 and headquartered in Germantown, MD. | Health Technology |
Forward Ventures Services LLC
 Forward Ventures Services LLC Investment ManagersFinance Forward Ventures Services LLC (Forward Ventures ) is a venture capital firm founded in 1990 by Standish M. Fleming and Ivor Royston. The firm is headquartered in San Diego, California. | Finance |
Amgen Rockville, Inc.
 Amgen Rockville, Inc. BiotechnologyHealth Technology Amgen Rockville, Inc. develops and commercializes antibody-based products. Its product development pipeline includes novel antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. The company was founded in 1993 and is headquartered in Rockville, MD. | Health Technology |
| LigoCyte Pharmaceuticals, Inc. | Health Technology |
San Diego Cancer Center
 San Diego Cancer Center Miscellaneous Commercial ServicesCommercial Services San Diego Cancer Center is a leading health system that offers primary and specialty care with state-of-the-art facilities. The private company is based in Vista, CA. The company has emergency rooms in various locations, including Chula Vista, and offer medical interpreters for patients with limited English proficiency or communication difficulties. The company also has urgent care centers in Rancho Bernardo and Oceanside, and offer a wide range of medical, surgical, and support services throughout San Diego. The company was founded by Mark J. Adler. | Commercial Services |
Sidney Kimmel Cancer Center
 Sidney Kimmel Cancer Center Medical/Nursing ServicesHealth Services Part of Sanford Burnham Prebys Medical Discovery Institute, Sidney Kimmel Cancer Center provides medical research services. The private company is based in San Diego, CA. Sidney Kimmel Cancer Center was acquired by Sanford Burnham Prebys Medical Discovery Institute on June 23, 2009 for $25 million. | Health Services |
HemaQuest Pharmaceuticals, Inc.
 HemaQuest Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology HemaQuest Pharmaceuticals, Inc. develops small molecule therapeutics. Its products include hydroxyurea, a therapeutic agent for the treatment of underlying pathology of sickle cell anemia and for the treatments of beta thalassemia, sickle cell anemia, neutropenia, and various hematological disorders. The company was founded by Ronald J. Berenson, Douglas V. Faller, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos and Robert Williams in October 2007 and is headquartered in San Diego, CA. | Health Technology |
CONNECT
CONNECT Miscellaneous Commercial ServicesCommercial Services CONNECT creates and scales companies in the technology and life sciences sectors. It creates an environment in which entrepreneurs and C-suite executives have access to the people, capital, and technology resources. The organization was founded in 1985 and is headquartered in San Diego, CA. | Commercial Services |
Altair Therapeutics, Inc.
Altair Therapeutics, Inc. Medical DistributorsDistribution Services Altair is a privately owned company that was spun out of ISIS Pharmaceuticals in October 2007 with the objective of applying ISIS’s proprietary second generation (2’-MOE Gapmer) antisense oligoneucleotide technology to the field of inhaled therapeutics. Through its collaboration with ISIS Altair has access to both near term clinical stage opportunities, as well as early stage development projects. Altair's first compound AIR645 is currently in phase I clinical trials. This first in class compound posses unique anti-inflammatory activities appropriate for multiple therapeutic applications, including asthma, rhinitis and COPD. Additionally, the characteristics of the 2'-MOE Gapmer chemistry provides for the possibility of administration of AIR645 as an inhaled therapeutic delivered once weekly. Altair is also planning on developing a future pipeline of other best-in-class molecules for respiratory targets by exploiting the advantages of its propriety 2nd generation antisense oligonucleotide chemistry. | Distribution Services |
La Jolla Playhouse, Inc.
 La Jolla Playhouse, Inc. Miscellaneous Commercial ServicesCommercial Services La Jolla Playhouse, Inc. provides educational opportunities for children, teens, and adults interested in theatre arts. The company was founded by Gregory Peck, Dorothy McGuire, and Mel Ferrer in 1947 and is headquartered in La Jolla, CA. | Commercial Services |
MMRGlobal, Inc.
 MMRGlobal, Inc. Information Technology ServicesTechnology Services MMRGlobal, Inc. provides secure and web-based storage solutions. The company serves consumers, healthcare professionals, employers, insurance companies, financial institutions, and professional organizations and affinity groups. Its product portfolio comprises of MyMedicalRecords, MyEsafeDepositBox, MMRPatientView and MMRPro. The company was founded in 2000 and is headquartered in Los Angeles, CA. | Technology Services |
IDEC Corp. (United States)
 IDEC Corp. (United States) Electrical ProductsProducer Manufacturing Part of IDEC Corp., the private company is a manufacturer and distributor of control equipment and related products. The company is based in Sunnyvale, CA and was founded by Ivor Royston. Toshiyuki Funaki has been the CEO of the company since 1975. | Producer Manufacturing |
The Life Sciences Foundation
 The Life Sciences Foundation Miscellaneous Commercial ServicesCommercial Services The Life Sciences Foundation engaged in education and biotechnology information dissemination. It collected and organized historical information to educate future innovators, to engage the general public, and to provide lay audiences with an understanding of life sciences and biotechnology. The company was founded by G. Steven Burrill, Dennis Gillings, John Lechleiter, Henri Termeer, and Arnold Thackray in 2010 and was headquartered in San Francisco, CA. | Commercial Services |
Viracta Subsidiary, Inc.
Viracta Subsidiary, Inc. BiotechnologyHealth Technology Viracta Subsidiary, Inc. engages in the development of proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr virus. Its platform is designed as a targeted approach to treat a range of viral-associated cancers and other serious diseases. The company was founded by Ronald J. Berenson, Douglas V. Faller, George C. Hillman, Thalia Papayannopoulou, Susan P. Perrine, George Stamatoyannopoulos, and Robert Williams and is headquartered in Cardiff, CA. | Health Technology |
